Associated tags: Food, TK, Genomics, COVID-19 testing, COVID-19, Research, Dietary supplement, CLIA, Prophase, OTC, DNA, Gene, Nebula Genomics, Laboratory, PCR, Severe acute respiratory syndrome coronavirus 2, Chromosome, Pharmaceutical industry, Vaccine
Locations: DOYLESTOWN, PA, US, NY, EUROPE
Retrieved on:
Tuesday, January 30, 2024
Prophase,
Growth,
Whole genome sequencing,
Therapy,
Karkus,
Nebula Genomics,
Marketing,
Genomics,
Acquisition,
Health,
Nebula,
WGS Garden City, NY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported that Jason Karkus, one of the driving forces behind ProPhase Diagnostics, becomes President of Nebula Genomics, a wholly-owned subsidiary of ProPhase Labs.
Key Points:
- Garden City, NY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported that Jason Karkus, one of the driving forces behind ProPhase Diagnostics, becomes President of Nebula Genomics, a wholly-owned subsidiary of ProPhase Labs.
- This fiscal achievement fueled ProPhase's growth and strategic acquisition of Nebula Genomics.
- In his new role, Karkus aims to amplify the Nebula Genomics business-to-business operations, as well as its exciting direct-to-consumer Whole Genome Sequencing (WGS) model.
- As ProPhase focuses on its WGS business lines, Karkus’ leadership, energy and vision are expected to be a driving force.
Retrieved on:
Tuesday, January 23, 2024
Garden City, NY, Jan. 23, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics, therapeutics and diagnostics company, today announces significant progress at Pharmaloz Manufacturing, Inc. (PMI), its wholly owned subsidiary.
Key Points:
- With the implementation of recent price increases across its entire product line, PMI has transitioned to significant projected 2024 profitability starting with Q1 2024.
- In addition to the price increases, increased capacity and transition to profitability, PMI has signed deals with two top-tier lozenge brands.
- One of these brands is also poised to leverage PMI's comprehensive blister packing capabilities, further diversifying its manufacturing portfolio.
- This production capacity could be further increased, if demand warrants it, with additional staffing to extend the workweek.
Retrieved on:
Thursday, January 4, 2024
Nebula Genomics,
CFO,
Prophase,
Acquisition,
Columbia,
Genomics,
Growth,
Acceleration,
Therapy,
Employment,
COVID-19,
Property management Garden City, NY, Jan. 04, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported that Jed Latkin, a long-time operations and finance expert, has accepted the role as COO of the parent company.
Key Points:
- Mr. Latkin, a Columbia MBA, represented the seller in the Company’s acquisition of the BE-SMART Esophageal Cancer Test.
- Mr. Latkin has been in the finance and management industry since 1996 and has worked with over 15 pharmaceutical companies over the last ten years alone.
- “We anticipate an acceleration in growth at both Nebula Genomics and Pharmaloz Manufacturing, as well as commercialization of our BE-SMART esophageal cancer test, during 2024.
- The options have an exercise price of $6.00 per share and will be exercisable for a period of seven years.
Retrieved on:
Thursday, November 9, 2023
Adjustment,
TK,
FDA,
Genetic counseling,
Nebula Genomics,
Research,
Sale,
Genomics,
Endoscopy,
CDX,
FDM,
Food,
Genetic,
Heart,
Therapy,
Hospital Insurance and Diagnostic Services Act,
COVID-19 testing,
Three Months,
History,
Public expenditure,
Omicron,
Diagnosis,
EBITDA,
Corporation,
Absorption,
Genetics,
Exercise,
Prophase,
House,
Whole genome sequencing,
Internet,
Health Resources and Services Administration,
COVID-19,
Medicine,
Marketing,
Stella,
WGS,
CPT,
Current Procedural Terminology,
Patient,
Anesthesia,
Automation,
Antibiotics,
Renewable energy,
Mobile phone,
Clothing,
Life insurance,
Security (finance),
Fine chemical,
Birth control,
Auction,
Broadcasting,
Pharmaceutical industry,
Cryptocurrency,
Bosc Garden City, NY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, therapeutics and diagnostics company, today reported its financial and operational results for the three and nine months ended September 30, 2023.
Key Points:
- Three Months Ended September 30, 2023 as compared to the Three Months Ended September 30, 2022.
- Net revenue for the three months ended September 30, 2023 was $8.4 million as compared to $24.2 million for the three months ended September 30, 2022.
- Diagnostic services costs for the three months ended September 30, 2023 were $0.1 million compared to $2.4 million for the three months ended September 30, 2022.
- Adjusted EBITDA loss for the three months ended September 30, 2023 was $(2.5) million compared to adjusted EBITDA income of $6.3 million for the three months ended September 30, 2023.
Retrieved on:
Thursday, November 2, 2023
Key Points:
- Participants can register for the conference call by navigating to: https://dpregister.com/sreg/10184034/faeb9e53fc
Please note that registered participants will receive their dial-in number upon registration.
- Pre-registration required fields of information include: name, phone, company, email.
- Please ask to be joined into the ProPhase Labs, Inc. conference call.
- A replay of the conference call will be available two hours from when the call ends.
Retrieved on:
Tuesday, October 17, 2023
Sustainability,
Therapy,
PMI,
FDA,
Growth,
CDMO,
Genomics,
Life,
Second line,
Renewable energy,
Fine chemical,
Marketing Garden City, NY, Oct. 17, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics, therapeutics and diagnostics company, today unveiled the substantial expansion strategy for its wholly-owned subsidiary, Pharmaloz Manufacturing, Inc. (PMI). Pharmaloz is a large lozenge manufacturing facility and Contract Development and Manufacturing Organization (CDMO) and is wholly owned by ProPhase Labs. Pharmaloz offers private label and other services to well-known brands, as well as manufacturing our own, proprietary products.
Key Points:
- Garden City, NY, Oct. 17, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics, therapeutics and diagnostics company, today unveiled the substantial expansion strategy for its wholly-owned subsidiary, Pharmaloz Manufacturing, Inc. (PMI).
- Pharmaloz is a large lozenge manufacturing facility and Contract Development and Manufacturing Organization (CDMO) and is wholly owned by ProPhase Labs.
- Pharmaloz offers private label and other services to well-known brands, as well as manufacturing our own, proprietary products.
- Pharmaloz offers its customers ultra-high-quality products and sources from ingredient suppliers who provide us with top-quality ingredients.
Retrieved on:
Thursday, October 12, 2023
GARDEN CITY, NY, Oct. 12, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics, therapeutics and diagnostics company, today announced it will be participating in The ThinkEquity Conference, which will take place on October 19, 2023 at The Mandarin Oriental Hotel in New York.
Key Points:
- GARDEN CITY, NY, Oct. 12, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics, therapeutics and diagnostics company, today announced it will be participating in The ThinkEquity Conference, which will take place on October 19, 2023 at The Mandarin Oriental Hotel in New York.
- ProPhase Labs’ CEO and Chairman of the Board of Directors, Ted Karkus will be presenting at 11:30 AM ET on October 19th.
- Interested parties can register to attend here:
One-on-one investor meetings will be held throughout the day.
- The presentation will also be live-streamed at the following link:
Retrieved on:
Thursday, August 10, 2023
Garden City, NY, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH)
Key Points:
- Garden City, NY, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH)
Management will host a conference call at 11:00 AM ET, Thursday, August 10, 2023, to provide an update on corporate developments and review financial results.
- Those without internet access or unable to pre-register may dial in by calling: 1-866-777-2509 (domestic), or 1-412-317-5413 (international).
- All callers should dial-in approximately 10 minutes prior to the scheduled start time and ask to be joined into ProPhase Lab’s call.
- A webcast replay of the call will be available approximately two hours after the end of the call at the above links.
Retrieved on:
Thursday, August 10, 2023
Nebula,
Mayo Clinic,
CPT,
Marketing,
Internet,
George Church,
Science,
Stella,
Nebula Genomics,
Patient,
Whole genome sequencing,
Hospital Insurance and Diagnostic Services Act,
Three Months,
Automation,
HRSA,
Heart,
Therapy,
Diagnosis,
Hope,
Research,
Endoscopy,
COVID-19 testing,
CLIA,
Corporation,
Medicine,
Genetic,
Growth,
Prophase,
System,
CDX,
IND,
Exercise,
DNA,
Operation Linebacker,
Absorption,
History,
Genetics,
Algorithm,
FDM,
Omicron,
Negotiation,
Genomics,
Cold,
Sale,
Public expenditure,
Genetic counseling,
EBITDA,
Food,
Renewable energy,
Pharmaceutical industry,
Retail,
Cryptocurrency,
Tourism,
Fine chemical,
Vaccine,
Microscope,
Q2,
COVID-19,
Bosc Garden City, NY, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported its financial and operational results for the three months ended June 30, 2023. The Company announced that despite the slowdown in the Covid-19 testing business, and the significant ramp-up of its multiple growth-oriented subsidiaries, adjusted EBITDA loss for the quarter ended June 30,2023 was $2.2 million in Q2 and that the Company enjoys robust net working capital of $40.2 million as of June 30, 2023.
Key Points:
- Company to hold a conference call Thursday, August 10, 2023, at 11:00 AM ET
Garden City, NY, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported its financial and operational results for the three months ended June 30, 2023.
- Revenues grew greater than 100% year-over-year for the six months ended June 30, 2023 as compared to the six months ended June 30, 2022.
- Three Months Ended June 30, 2023 as compared to the Three Months Ended June 30, 2022.
- Diagnostic services costs for the three months ended June 30, 2023 were $0.6 million compared to $1.8 million for the three months ended June 30, 2022.
Therapy,
LB-1,
Cancer,
Genomics,
Burn,
Linebacker,
Machine learning,
Artificial intelligence,
Prophase,
Karkus,
IND,
Pharmaceutical industry,
Medical device,
Certis Group “We have tested the novel Linebacker compound against hundreds of cancers and thousands of pathways, but will continue testing to the extent we believe useful data may be obtainable,” says Ted Karkus, CEO of ProPhase Labs.
Key Points:
- “We have tested the novel Linebacker compound against hundreds of cancers and thousands of pathways, but will continue testing to the extent we believe useful data may be obtainable,” says Ted Karkus, CEO of ProPhase Labs.
- “Our team is very pleased to be working with ProPhase on the Linebacker initiative.
- “Savvy investors expect this now, and with good reason, and ProPhase will continue to lead the pack and push the boundaries forward.
- We are looking forward to initiating Phase I human studies next year at a modest budget of approximately $3+ million dollars for all planned studies.
